Biocon

Biocon Limited is an Indian biopharmaceutical company headquartered in Bengaluru. Its business spans generic active pharmaceutical ingredients, finished formulations, biosimilars, novel biologics, peptides, and contract research and development through associated companies. The company serves the Indian market and exports pharmaceutical products to international markets, including the United States, Europe, Japan, and other emerging economies. Its therapeutic focus includes diabetes and metabolic disease, oncology, immunology, nephrology, and selected areas of infectious disease. Kiran Mazumdar-Shaw established Biocon India Private Limited in 1978 with relatively modest startup capital, initially as an Indian partner to the Irish enzyme producer Biocon Biochemicals. The company began with industrial enzymes used in brewing and related applications, including papain and isinglass. In 1979, it became the first Indian company to manufacture and export enzymes to the United States and Europe. During the 1980s, Biocon gradually moved toward pharmaceutical production and began building capabilities in active pharmaceutical ingredients and regulated manufacturing. A significant corporate transition followed the acquisition of Biocon Biochemicals by Unilever in 1989 and its integration with Quest International. Unilever later sold its interest to Biocon’s Indian owners in 1998, reconnecting the Indian operation with the business from which it had originated. During the 1990s and 2000s, Biocon expanded from commodity and specialty ingredients into higher-value pharmaceutical products, research services, and biologic medicines. Syngene International, established in 1993, became the group’s contract research and development platform and later operated as a separately listed company. Biocon’s international expansion accelerated in the 2000s and 2010s. It developed manufacturing and commercial partnerships with multinational pharmaceutical companies, established or expanded facilities in India and Malaysia, and created Biocon Biologics as a dedicated biosimilars business. Regulatory approvals in the United States, Europe, Japan, and other markets supported the company’s transition from an India-focused manufacturer into a global supplier. Its portfolio came to include biosimilar insulin, monoclonal antibodies, and oncology products, alongside APIs and branded formulations for India. The company’s best-known product areas include insulin and insulin analogues, including Insugen and Basalog; oncology and immunology biologics such as CANMAb, KRABEVA, BIOMAb EGFR, and ALZUMAb; and generic and branded medicines such as Evertor and Tacrograf. Biocon has often positioned biosimilars as a means of broadening access to complex medicines whose originator products are expensive. Its products may be supplied as bulk drug substance, finished formulations, or branded medicines, depending on the market and commercial arrangement. Biocon Biologics became the central vehicle for the group’s global biosimilars strategy. The business entered major collaborations with Mylan, later associated with Viatris, and reached approvals for products including trastuzumab and insulin glargine. In 2021, Biocon Biologics and Viatris launched Semglee in the United States, which became the first interchangeable biosimilar insulin glargine product approved there. In 2022, Biocon Biologics acquired Viatris’s biosimilars business, materially increasing its commercial footprint and product portfolio. Biocon’s broader group also includes research and development capabilities through Syngene and other subsidiaries and partnerships. The company has collaborated with organizations including Bristol Myers Squibb, Amgen, Sandoz, Serum Institute of India, Vaccinex, Abraxis BioScience, Amylin Pharmaceuticals, and CIMAB. Its current identity is therefore that of an integrated life-sciences group combining pharmaceutical manufacturing, biosimilars, biologics development, and outso…

Biocon was founded in 1978 as Biocon India Private Limited by Kiran Mazumdar-Shaw. The enterprise was created as an Indian partner to Biocon Biochemicals, an Irish company known for brewing enzymes. With limited initial capital, the Indian operation began by making industrial enzymes, including papain derived from papaya and isinglass used as a clarifying agent in brewing and winemaking. In 1979, it became the first Indian company to manufacture and export enzymes to the United States and Europe. During the 1980s, Biocon broadened its activities and began producing increasing amounts of pharmaceutical material for the Indian market. The ownership history of its Irish partner affected the group’s structure: Unilever acquired Biocon Biochemicals in 1989 and combined it with Quest International. In 1998, Unilever sold its interest to Biocon’s Indian owners, effectively reuniting the businesses. Biocon established Syngene in 1993 to provide outsourced research and development services. Syngene subsequently developed into a major contract research, development, and manufacturing organization serving global pharmaceutical and biotechnology companies. Biocon also created Biocon Biopharmaceuticals in 2003 with Cuba’s CIMAB to develop and market monoclonal antibodies and cancer vaccines. The company’s strategic direction increasingly shifted toward APIs, branded formulations, biologics, and complex generic products. It acquired a majority stake in German pharmaceutical marketing company AxiCorp in 2008 and established NeoBiocon in Abu Dhabi during the same period. In 2009, Biocon entered a collaboration with Mylan to develop and commercialize generic biologics, creating the basis for a long-running international biosimilars relationship. Biocon also formed research and development collaborations with companies such as Bristol Myers Squibb and Amgen. During the 2010s, Biocon expanded manufacturing and research capacity in India and Malaysia while developing novel biologics and biosimilars. Products introduced or advanced during this period included ALZUMAb, an itolizumab-based antibody used in immunology; CANMAb, a trastuzumab biosimilar for breast cancer; and CIMIVIR-L, a ledipasvir-sofosbuvir product for hepatitis C. Biocon’s portfolio also included insulin products, oncology medicines, immunotherapies, and nephrology treatments. Biocon Biologics became the group’s principal biosimilars platform. In 2016, it launched a biosimilar insulin glargine pen in Japan, becoming the first Indian company to do so. U.S. approval of a trastuzumab biosimilar followed in 2017, while European approval for biosimilar insulin glargine followed in 2018. In 2021, Biocon Biologics and Viatris launched Semglee in the United States; the product was the first interchangeable biosimilar insulin glargine approved in that market. Biocon also entered a strategic arrangement with Serum Institute of India involving a minority investment in Biocon Biologics, vaccine access, and international commercialization rights. In 2022, Biocon Biologics acquired Viatris’s biosimilars division. The transaction increased Biocon’s direct commercial capabilities across major pharmaceutical markets and reinforced its focus on diabetes, oncology, and immunology. Biocon later announced plans to integrate Biocon Biologics as a wholly owned subsidiary, consolidating its generics and biosimilars operations within one listed group. Biocon also acquired Biofusion Therapeutics in 2023. The group today combines pharmaceutical manufacturing, biosimilars, biologics, APIs, branded formulations, and contract research services, with operations and partnerships extending well beyond India.

1. 2023Biofusion Therapeutics acquisition

   Biocon purchases Biofusion Therapeutics Limited.

   Source
2. 2022Viatris biosimilars acquisition

   Biocon Biologics acquires Viatris’s biosimilars business.

   Source
3. 2021Semglee receives U.S. interchangeability approval

   Semglee becomes the first interchangeable biosimilar insulin in the United States.

   Source
4. 2017U.S. trastuzumab biosimilar approval

   The Biocon–Mylan partnership receives U.S. approval for a biosimilar of Herceptin.

   Source
5. 2016Japanese insulin glargine launch

   Biocon becomes the first Indian company to launch a biosimilar insulin glargine pen in Japan.

   Source
6. 2009Mylan biosimilars collaboration begins

   Biocon and Mylan agree to develop and commercialize generic biologics internationally.

   Source
7. 2008AxiCorp stake acquired

   Biocon acquires a 70 percent stake in German pharmaceutical marketing company AxiCorp.

   Source
8. 2003Biocon Biopharmaceuticals is formed

   Biocon and CIMAB create a joint venture focused on monoclonal antibodies and cancer vaccines.

   Source
9. 2001Lovastatin production receives regulatory recognition

   Biocon’s international biologics and pharmaceutical manufacturing expansion includes regulatory acceptance beginning with lovastatin.

   Source
10. 1993Syngene is established

    Biocon establishes Syngene as a contract research and development platform.

    Source
11. 1979First enzyme exports to the United States and Europe

    Biocon becomes the first Indian company to manufacture and export enzymes to the United States and Europe.

    Source
12. 1978Biocon India is founded

    Kiran Mazumdar-Shaw establishes Biocon India Private Limited as an Indian partner to Biocon Biochemicals.

    Source

A vertically integrated Indian biopharmaceutical group focused on affordable complex medicines, biosimilars, biologics, APIs, and research services for domestic and global markets.

• InsugenRecombinant human insulin

  Insugen is Biocon’s branded recombinant human insulin line for diabetes treatment. It represents the company’s long-standing capability in insulin manufacturing and its focus on supplying more affordable diabetes therapies, particularly in India and other emerging markets. The line is part of Biocon’s broader diabetes portfolio, which also includes insulin analogues and biosimilar products.

• BasalogInsulin analogue

  Basalog is Biocon’s branded insulin glargine product. It is used as a long-acting basal insulin for diabetes management and illustrates Biocon’s movement from conventional pharmaceutical ingredients into complex biologic medicines and insulin analogues. The product has been associated primarily with the Indian branded-formulations market.

• SemgleeBiosimilar insulin2021

  Semglee is an insulin glargine-yfgn biosimilar developed by Biocon Biologics with Viatris. In 2021, it became the first interchangeable biosimilar insulin glargine approved in the United States. Its development and commercialization marked a major step in Biocon’s international diabetes strategy and in the broader adoption of biosimilar insulin.

• CANMAbBiosimilar monoclonal antibody2014

  CANMAb is Biocon’s trastuzumab biosimilar for oncology, particularly breast-cancer treatment. It is one of the company’s prominent monoclonal-antibody products and formed part of Biocon’s effort to make expensive biologic cancer therapies more accessible in India and other markets.

• KRABEVABiosimilar monoclonal antibody

  KRABEVA is Biocon’s branded bevacizumab biosimilar for oncology. It belongs to the company’s portfolio of complex biologic medicines and supports treatment applications in which access to anti-angiogenic cancer therapy is important. Availability and approved indications vary by market.

• BIOMAb EGFRMonoclonal antibody

  BIOMAb EGFR is a nimotuzumab-based monoclonal antibody used in oncology. It is part of Biocon’s India-focused branded biologics portfolio and reflects the company’s early investment in proprietary or partnered antibody products rather than relying exclusively on small-molecule generics.

• ALZUMAbMonoclonal antibody2013

  ALZUMAb is an itolizumab-based biologic associated with treatment of psoriasis and other immunological conditions. Introduced during Biocon’s expansion into novel biologics, it demonstrates the company’s interest in developing differentiated antibody therapies alongside biosimilars.

• CIMIVIR-LAntiviral combination2015

  CIMIVIR-L combines ledipasvir and sofosbuvir for hepatitis C treatment. It represents Biocon’s branded pharmaceutical activity in infectious disease and its ability to commercialize complex combination products for the Indian market.

• EvertorOncology and specialty medicine

  Evertor is Biocon’s branded everolimus product. Everolimus is used in several specialty-care settings, including oncology and transplant-related treatment, depending on the approved indication and market. The brand is part of Biocon’s Indian formulations portfolio.

• TacrografImmunosuppressant

  Tacrograf is Biocon’s branded tacrolimus product, used as an immunosuppressive medicine in transplantation and related specialty-care settings. It illustrates the company’s presence in nephrology and other areas requiring long-term, closely managed therapies.

• 2025Planned full integration of Biocon BiologicsM&A

  Biocon stated that a unified structure could reduce complexity and avoid the valuation discount associated with a separately held biosimilars subsidiary.

  What changed. Biocon announced a plan to make Biocon Biologics a wholly owned subsidiary through share swaps and the purchase of remaining minority interests.

  Aftermath. The planned transaction would combine the group’s generics, biosimilars, insulin, and peptide operations under the listed Biocon entity.

  Valuation of Biocon Biologics. US$5.5 billion (2025)

  Source
• 2022Acquisition of Viatris biosimilars businessM&A

  Biocon Biologics aimed to obtain direct commercial control and a larger global portfolio after years of partnering with Viatris and its predecessor Mylan.

  What changed. Biocon Biologics acquired Viatris’s global biosimilars business, including associated commercial capabilities and products.

  Aftermath. The acquisition materially increased Biocon’s presence in the United States, Europe, and other regulated markets.

  Transaction value. US$3.335 billion (2022)

  Source
• 2021Serum Institute partnership for vaccines and biologicsStrategy

  Biocon sought to broaden its biologics platform and gain access to large-scale vaccine supply while Serum Institute sought an international commercialization partner.

  What changed. Biocon Biologics entered a joint arrangement with Serum Institute of India, including a minority investment and cooperation on vaccines, biological drugs, and antibody therapies.

  Aftermath. The arrangement expanded Biocon’s potential international vaccine and biologics portfolio and linked the group to Serum Institute manufacturing capacity.

  Implied valuation of Biocon Biologics. US$4.9 billion (2021)

  Source
• 2009Global generic-biologics collaboration with MylanStrategy

  Biocon sought to expand beyond India by using Mylan’s international commercial infrastructure for generic biologics and biosimilars.

  What changed. The companies agreed to develop and commercialize a portfolio of generic biologics, with Mylan receiving commercial rights in several major markets under a profit-sharing arrangement.

  Aftermath. The collaboration became a foundation for later biosimilar approvals and the eventual transfer of Viatris’s biosimilars business to Biocon Biologics.

  Source

• 2025Biocon announces integration of Biocon Biologics

  Biocon announced a plan to make Biocon Biologics a wholly owned subsidiary rather than pursue a separate public listing for the biosimilars business.

  M&A
  Source
• 2022Biocon Biologics acquires Viatris biosimilars business

  Biocon Biologics agreed to acquire Viatris’s global biosimilars business, substantially broadening its commercial infrastructure and portfolio.

  M&A
  Source
• 2021Biocon Biologics and Serum Institute announce strategic partnership

  The companies agreed to collaborate on commercialization of vaccines, biologics, and antibody therapies, with Serum Institute taking a minority interest in Biocon Biologics.

  M&A
  Source
• 2021Semglee becomes the first interchangeable biosimilar insulin in the United States

  Biocon Biologics and Viatris launched insulin glargine-yfgn after U.S. approval as an interchangeable biosimilar insulin.

  Product launchProduct generation
  Source
• 2018European approval for Biocon and Mylan insulin glargine biosimilar

  European regulators approved the partners’ biosimilar insulin glargine, supporting expansion in diabetes care.

  Product launchOther
  Source
• 2017Biocon and Mylan receive U.S. approval for a trastuzumab biosimilar

  The partners received U.S. regulatory approval for a biosimilar of Herceptin, expanding Biocon’s oncology biologics presence in the American market.

  Product launchOther
  Source

1. Biocon
2. Biocon official website